ORIGINAL ARTICLE

Oxidative stress biomarkers in sporadic ALS

HIROSHI MITSUMOTO 1,2, REGINA M. SANTELLA 3, XINHUA LIU 4, MIKHAIL BOGDANOV 6, JENNIFER ZIPPRICH 3, HUI-CHEN WU 3, JULIE MAHATA 3, MARY KILTY 1,2, KATE BEDNARZ 1,2, DANIEL BELL 1,2, PAUL H. GORDON 1,2, Mady Hornig 4, Mahsa Mehrazin 2, Ali Naini 2, M. FLINT BEAL 6 & Pam Factor-Litvak 5

1 Eleanor and Lou Gehrig MDA/ALS Research Center, 2 Department of Neurology, Columbia University Medical Center, New York, NY, Departments of 3 Environmental Health Sciences, 4 Biostatistics and 5 Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, and 6 Department of Neurology and Neurosciences, Weill Medical School, Cornell University, New York, NY, USA

Abstract

We aimed to investigate oxidative stress biomarkers in a cross-sectional pilot study of 50 participants with sporadic ALS (SALS) compared to 46 control subjects. We measured urinary 8-oxodeoxyguanosine (8-oxodG), urinary 15-F2t-isoprostane (IsoP), and plasma protein carbonyl by ELISA methods. We also determined if ELISA measurement of 8-oxodG could be validated against measures from high-pressure liquid chromatography coupled with electrochemical detection, the current standard method. We found that 8-oxodG and IsoP levels adjusted for creatinine were significantly elevated in SALS participants. These differences persisted after age and gender were controlled in regression analyses. These markers are highly and positively correlated with each other. 8-oxodG measured by the two techniques from the same urine sample were positively correlated (p < .0001). Protein carbonyl was not different between SALS participants and controls. In conclusion, using ELISA, we confirmed that certain oxidative stress biomarkers were elevated in SALS participants. ELISA may be reliable and thus useful in epidemiology studies requiring large numbers of samples to determine the significance of increased oxidative stress markers in SALS. Further studies are required.

Key words: Epidemiology, amyotrophic lateral sclerosis (ALS), biomarkers, oxidative stress, neurodegeneration

Introduction

Despite decades of intense research efforts and a number of highly plausible hypotheses, the cause of sporadic ALS (SALS) has not been determined (1). Factors related to the risk of developing SALS have only recently been extensively investigated. It is considered a multifactorial and complex disease, i.e. genetic, environmental, or genetic-environmental interactions may lead to motor neuronal degeneration (2,3). Oxidative stress, a condition whereby the pro- and anti-oxidant balance is disrupted, increases reactive oxygen and nitrogen species (ROS, RNS), which damage cellular constituents of motor neurons and surrounding cells. Oxidative stress has been closely associated with motor neuron degeneration in SALS (3–5).

Several recent clinical studies support an oxidative stress hypothesis, as a number of biomarkers for oxidative stress have been found abnormal in ALS (6–11). In particular, Bogdanov et al. (6) showed that in 65 participants newly diagnosed with SALS, 63 healthy participants and 37 participants with non-ALS neurological disorders, 8-oxo (or 8-hydroxy) deoxyguanosine (8-oxodG), a marker of DNA damage and repair, was elevated in cerebral spinal fluid (CSF), plasma and urine only in SALS participants (6). In all participants, plasma and CSF 8-oxodG levels increased with age, providing evidence, as expected, that oxidative damage is associated with normal aging. In another study, the lipid peroxidation product 4-hydroxy-2,3-nonenal was elevated in CSF and serum in participants with SALS compared to normal controls (7). These
studies suggest that certain blood and urinary biomarkers might be used to study oxidative stress in patients with SALS.

A number of epidemiological studies conducted in participants with SALS suggest that diverse environmental and lifestyle factors are associated with the occurrence of SALS. Many of these purported risk factors may generate systemic oxidative stress (see Discussion below). To explore possible associations between these environmental/lifestyle factors, oxidative stress and SALS, a well-designed molecular epidemiological study is necessary. For such a study, efficient and reliable measurement techniques for oxidative stress biomarkers are crucial. Therefore, in a pilot study we analyzed whether these biomarkers differ significantly between participants with SALS and healthy participants.

We chose the three most frequently utilized and easily accessible oxidative stress biomarkers (12). 8-oxodG is one of the principal DNA adducts, derived from mitochondrial DNA and nuclear DNA (13,14). 15-F_{2\alpha}-isoprostane (IsoP) is derived from arachidonic acid via a free radical-catalyzed mechanism. It is used extensively as a clinical biomarker in various diseases including Alzheimer’s disease (15,16). DNA adducts and lipid peroxidation products indicate current oxidative stress, while plasma protein carbonyl, an end-product of intracellular amino acids damaged by excessive ROS, indicates longer-term (approximately three months) oxidative stress (17).

Materials and methods

Study subjects

After receiving Institutional Review Board and HIPAA approvals at Columbia University Medical Center, we collected plasma and urine samples from volunteers at the Eleanor and Lou Gehrig MDA/ALS Research Center – 50 participants with sporadic ALS (SALS) and 46 controls. The diagnosis of SALS was made based on El Escorial ALS diagnostic criteria (18) and included definite, probable, laboratory-supported probable and possible ALS. The diagnosis of SALS was primarily based on no family history of ALS and, for a very few participants, SOD1 molecular testing with negative results. Spouses, siblings, children and friends of SALS participants were asked to volunteer as controls if they were free of neurodegenerative disease and clinically healthy without any specific selection scheme. This pilot study was cross-sectional in design. There was no restriction as to food and medication intake prior to specimen collection, and all specimens were obtained during the daytime.

Demographic data including age and gender were obtained for all subjects. In the participants with SALS, disease duration (time from clinically recognizable symptom onset to examination date) was ascertained, and ALSFRS-R (19) and FVC were measured.

Biomarker measurements

All assays were conducted with laboratories blinded to status as a participant with SALS or a control.

Urinary 8-oxodG levels. These levels were determined by competitive ELISA essentially as described previously (20). Briefly, wells were coated with 8-oxoG conjugated with BSA. 8-oxoG standards (concentration range 5–80 ng/ml) and urine samples (diluted 1:1 with PBS) were assayed with antibody 1F7 (20). Incubation with secondary antibody conjugated with alkaline phosphatase was followed by incubation with p-nitrophenyl phosphate.

Urinary 8-oxoG. This was determined by high pressure liquid chromatography (HPLC) and electrochemical detection (ECD) as previously described (21). Briefly, the method is based on the unique purine selectivity of porous carbon columns that allows routine accurate measurement of 8-oxoG in a variety of biological matrices. Samples are injected onto a C_{18} column, and the band containing 8-oxoG is then quantitatively trapped on a carbon column. The selectivity of the carbon column for 8-oxoG allows elimination of interfering peaks by washing the column with a second mobile phase, followed by elution of 8-oxoG to a C_{18} column with an identical mobile phase containing adenosine to displace 8-oxoG. Detection with series coulometric electrodes provides 0.5 pg sensitivity for 8-oxoG and qualitative certainty by response ratios. Because urinary 8-oxoG concentration depends on individual urinary output, it was normalized using urinary creatinine levels, assayed using a kit from Sigma (St. Louis, MO; Cat. No. 555-A) (22).

Urinary 15-F_{2\alpha}-isoprostane (IsoP). This was analyzed using immunoassay kits from Oxford Biomedical Research (Oxford, MI; Product No. EA 85) according to the manufacturer’s recommendations. As 8-oxoG, urinary IsoP was also normalized using urinary creatinine levels as described above.

Plasma protein carbonyl. Plasma oxidized protein was measured as follows. The concentration of total plasma proteins was determined using the BioRad BCA assay in 96-well plates. Plasma was diluted to 4 mg/ml and derivatization by dinitrophenyl hydrazine was carried out essentially as described (23). A standard curve for the non-competitive ELISA was generated by mixing sodium borohydride-reduced
and HOCl-oxidized bovine serum albumin (BSA), prepared as described (23). Carbonyl concentration in the BSA standard was calculated colorimetrically (A375 nm). Standard protein solutions were derivatized with DNPH then adsorbed into the wells of an ELISA plate as for the test samples, before incubating with biotin conjugated anti-DNPH antibody (Molecular Probes, Eugene, OR). The biotin-conjugated primary antibody was then detected with streptavidin-biotinylated horseradish peroxidase.

Statistical analyses. Variables with skewed distributions were appropriately transformed to reduce the impact of extreme values in the statistical analysis. Since some variables had skewed distributions and were dissimilar within group variances, we used the non-parametric Wilcoxon’s rank sum test to assess differences between subjects with ALS and controls. Patient-control differences in categorical variables were assessed using χ² tests. Additionally, we estimated correlations between continuous variables using Spearman correlation methods. Finally, we estimated the associations between biomarkers of oxidative stress and SALS using logistic regression, controlling for age and sex.

Results

Table I summarizes the clinical features of participants with SALS and controls, along with the results of the oxidative marker measurements. Cases were more likely to be male, and were older than controls. Urinary IsoP and urinary 8-oxodG were higher among cases than among controls, before adjustment for urine concentration (urinary creatinine). As expected (24,25), 8-oxodG (adjusted for creatinine) increased with age \( (r=0.30, p=.004) \). No relationship was found between age and urinary IsoP (adjusted for creatinine). Plasma protein carbonyl levels were not different between patients and controls before and after adjustment for age.

Urinary 8-oxodG levels (adjusted for creatinine) were significantly higher in SALS participants than in controls \( (p=.036) \). Data distribution for cases and controls is shown in Figure 1a. Using logistic regression analysis controlling for sex and age, we found a positive association between SALS and the natural log of urinary 8-oxodG (adjusted for creatinine). The odds ratio \((95\% CI 1.26–7.14; p-value=.001)\) was 3.01 for doubling the exposure level of urinary 8-oxodG (adjusted for creatinine).

Urinary IsoP levels (adjusted for creatinine) were significantly higher in SALS participants than in controls \( (p=.002) \). Data distribution for cases and controls is shown in Figure 1b. Using logistic regression controlling for sex and age, we found a positive association between SALS and the natural log of urinary IsoP (adjusted for creatinine). The odds ratio \((95\% CI 1.40–7.55; p-value=.006)\) was 3.24 for doubling the exposure level of urinary IsoP (adjusted for creatinine).

Levels of 8-oxodG measured by ELISA and HPLC/ECD using the same urine specimens were correlated although values measured by ELISA were higher than those measured by HPLC/ECD (21). The Spearman correlation coefficient was .545 \((p < .0001)\) (Figure 2).

Figure 1c shows the data distribution for urinary 8-oxodG levels (adjusted for creatinine) as measured by HPLC/ECD. These levels were significantly higher in SALS participants than in controls \( (p=.004) \). Using logistic regression controlling for sex and age, we found a positive association between SALS and the natural log of urinary 8-oxodG (adjusted for creatinine). The odds ratio \((95\% CI 1.16–3.51; p-value=.012)\) was 2.02 for doubling the exposure level.

Table I. 8-oxodG, IsoP and protein carbonyl, and disease status measures in sporadic ALS patients and controls.

<table>
<thead>
<tr>
<th>Variable</th>
<th>ALS subjects ((n=50^*))</th>
<th>Control subjects ((n=46^*))</th>
<th>(p)-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>S.D.</td>
<td>Range</td>
</tr>
<tr>
<td>Male (%)</td>
<td>61</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Age (years)</td>
<td>61</td>
<td>12</td>
<td>23, 80</td>
</tr>
<tr>
<td>ALSFRS-R score</td>
<td>31</td>
<td>9</td>
<td>8, 46</td>
</tr>
<tr>
<td>FVC (% of predicted)</td>
<td>77</td>
<td>23</td>
<td>16, 120</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>3</td>
<td>2</td>
<td>1, 13</td>
</tr>
<tr>
<td>Urinary Isoprostane** (nmol/l)</td>
<td>7</td>
<td>6</td>
<td>0.3, 24</td>
</tr>
<tr>
<td>8-oxodG** (nmol/l)</td>
<td>415</td>
<td>214</td>
<td>31, 1301</td>
</tr>
<tr>
<td>Plasma protein carbonyl** (nmol/ml)</td>
<td>24</td>
<td>12</td>
<td>6, 59</td>
</tr>
<tr>
<td>Creatinine (mmol/l)</td>
<td>9</td>
<td>6</td>
<td>1, 30</td>
</tr>
<tr>
<td>Urinary Isoprostane/creatinine* (nmol/mmol)</td>
<td>0.8</td>
<td>0.8</td>
<td>0.3, 5.0</td>
</tr>
<tr>
<td>8-oxodG/creatinine* (nmol/mmol)</td>
<td>57</td>
<td>38</td>
<td>16, 203</td>
</tr>
</tbody>
</table>

*While \(n = 50\) for ALS subjects and \(n = 46\) for controls in total, there was a limited number of missing data points for some variables because biological samples were unavailable or not usable or clinical data were not obtained. For any given variable among cases, the lowest \(n\) is equal to 42 and for controls, the lowest \(n\) is equal to 41.

**Each measured by ELISA methods.
Correlation among oxidative markers

As expected, 8-oxodG and IsoP had a significant positive Spearman correlation ($r = .70$, $p < .001$). 8-oxodG measured by HPLC also had a significant Spearman correlation with isoprostane ($r = .60$, $p < .001$). There was no significant Spearman correlation between either of these two markers and plasma protein carbonyl.

Correlation between OS biomarkers and clinical measures

No significant Spearman correlations were found between both 8-oxodG and IsoP (both adjusted for creatinine) and the clinical measures of ALSFRS-R and FVC. Repeated measures of ALSFRS-R and FVC prior to and including the date of urine collection were available in 20 patients with ALS. The trend in these clinical measures was not significantly associated with the 8-oxodG and IsoP (adjusted for creatinine).

Discussion

Two out of the three oxidative stress biomarkers measured in this cross-sectional study, the oxidized DNA adduct and the lipid peroxidation product, were significantly increased in SALS participants compared to controls. In addition, the correlation coefficient between the ELISA and HPLC/ECD methods in measuring 8-oxodG of the same urine specimen was 0.545 ($p < .0001$), which was significant; however, for the definitive reliability study a higher coefficient is desirable. The ELISA values were usually 10–20-fold higher than those by HPLC. While the HPLC method measures a single compound, the ELISA method can detect 8-oxoguanine, 8-oxoG and 8-oxodG as well as oligonucleotides containing 8-oxodG. There is also some cross-reactivity with guanine and structurally related derivatives such as 8-mercaptoguanosine (20). A previous study comparing HPLC and ELISA methods measuring 8-oxodG, found the ELISA method more reliable when repeated measures were used (26). When using ELISA techniques, additional care must be taken in order to reduce variability, such as collecting the urine specimen in the morning after fasting and before any medications are taken.

In contrast to urinary 8-oxodG and IsoP, protein carbonyl levels did not differ between participants with SALS and controls. 8-oxodG and IsoP were strongly correlated with each other but not with protein carbonyl, indicating that the oxidative biomarkers we measured are measuring different aspects of oxidative stress. Therefore, it is important to
analyze several biomarkers when studying oxidative stress in SALS.

If oxidative stress markers are increased in SALS, what is the biological mechanism underlying this increase? A previous study of 8-oxodG in CSF, plasma and urine in patients with ALS found that the plasma levels of DNA adduct were elevated far more than expected if CSF was the sole source of elevated oxidative stress marker levels, suggesting that increased oxidative stress found in blood and urine are likely derived from outside of the CNS (6). A recent series of studies suggests the possibility of systemic involvement in SALS (27). In ALS patients, cultured monocytes have increased inflammatory cytokine production (28), cutaneous collagen fibers are abnormal (29), systemic glutamate metabolism is impaired (30), the antioxidative defense system of erythrocytes is reduced (31), patients are in a hypermetabolic state due to abnormal skeletal muscle metabolism (32), and muscle mitochondria are not only structurally abnormal (33,34), but have primary abnormalities known to cause an ALS-like syndrome (35). A major source of 'systemic' oxidative stress is clearly generated in skeletal muscle, which constitutes 40–45% of body mass (36). All these reports thus suggest that SALS may have increased oxidative stress in the system outside of the central nervous system.

Another crucial question regarding increased oxidative stress in SALS is specificity. Recent studies have suggested that abnormal oxidative stress may be a common process in a number of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease (37–41) and in a number of severe chronic systemic diseases (36). The latter examples include advanced cancer (42), severe chronic obstructive pulmonary disease (43), renal failure (44), and HIV, all of which cause development of cachexia in relation to underlying oxidative stress. These observations suggest that oxidative stress may be a common path leading to severe chronic systemic diseases (36). Cachexia in ALS is a unique problem first pointed out by Norris (45), in which severe cachexia may develop without much muscle atrophy in some patients (46). However, we must investigate in a prospective study whether increased oxidative stress has any causal relationship to progressive weight loss in ALS.

There are a number of factors that have been associated with ALS (47). Most factors listed are known to cause systemic oxidative stress in vivo and in vitro studies, including a number of agricultural chemicals (48–50): lead and other heavy metals (51–54) and electromagnetic fields (55). Specific lifestyle factors such as excessive physical exertion, smoking, consumption of glutamate-rich and high-fat foods are also shown to generate systemic oxidative stress (50,56–58). The factors involved in military service are complex, but such activities may similarly cause significant oxidative stress (59–61).

The relationship between environmental and lifestyle factors and increased oxidative stress in patients with SALS must be established more clearly.

Our study had a number of limitations, primarily because it was designed as a cross-sectional pilot study. For example, only a small number of SALS participants had clinical measures that could be evaluated with oxidative marker measures. There were also large overlaps in the levels of oxidative stress markers between participants with SALS and controls. Although results clearly suggest underlying pathomechanisms, these markers cannot be used for clinical diagnostic purposes. In this pilot study, urine and blood samples were obtained whenever available from the subjects. This may be partly responsible for the differences in 8-oxodG levels by ELISA and HPLC. The ELISA is known to cross-react with structurally similar compounds, as discussed earlier. For future studies, we will need to strictly control the timing of specimen sampling, fasting status, and medication status upon blood and urine sampling. Another limitation was the selection of controls, which were not age and gender matched although these variables were controlled in a logistic regression analysis. Matched controls are preferred for future studies to ensure adequate control for potentially confounding variables.

This study demonstrated that urine, which is simple and convenient to collect, can be useful in biomarker studies. In addition, the ELISA method for 8-oxodG and IsoP measurements was found to be reliable at least at one point in time. This is important because ELISA is more suitable for a study with a large sample size because it is less time-consuming and expensive than the HPLC. This pilot study provides strong evidence that a molecular epidemiological study using ELISA methods to measure oxidative stress markers is feasible.

Acknowledgements

This study was funded by the Center for Environmental Health in Northern Manhattan (P30ES09089 – Regina Santella, PI), the Muscular Dystrophy Association, the Wings Over Wall Street Fund, the Ride for Life, the Spina Golf for Life, the Adams Foundation and by the generous donations of individuals. Linda Ali Cruz coordinated the initial part of the study. Jonathan Sandner assisted with additional data collection. We thank the volunteers, their families, and their friends for participating in this study.

References


